Cell Line Development: Stable cell lines are widely used in a number of important applications including biologics (e.g. recombinant protein and monoclonal antibody) production, drug screening, and gene functional studies. The process of developing stable cell lines often starts with transfecting selected host cells, typically CHO or HEK 293 cells, with desired plasmids. After transfection, researchers then screen and quantify high-expressing clones. Once these high producers are identified, the cell lines and/or the proteins produced by the cells are validated. The manual screening methods traditionally used for cell line development are time-consuming and labor-intensive, creating a great demand for high-throughput, automated solutions for such efforts.
-
DATE: September 18, 2018TIME: 9:00AM PDTLC-MS/MS has been increasingly adopted by clinical laboratories due to the potential it has for increased sensitivity and specificity over m...
DATE: September 18,2018TIME: 08:00am PDT, 11:00am EDT CRISPR-Cas9 gene editing strategies have revolutionized our ability to engineer the genomes of diverse cell types and sp...
DATE: September 12, 2018 TIME: 08:00am PDT, 11:00am EDT In the last presentation of this webinar series, we will continue our discussions on recent advancements i...
DATE: September 11, 2018TIME: 07:00AM PDTWith increasing safety requirements, and time and financial pressure, the development of new drugs, and the execution of basic research p...
DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
With the advent of cost effective culturing approaches, 3D cell culture models (3D-CCMs) have been rapidly adopted for drug discovery since they provide a more physiologically relevant micro-...
DATE: August 7, 2018TIME: 08:00AM PDT, 11:00AM EDTWe are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is drivi...
DATE: July 19, 2018TIME: 09:00am PDT Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a 5 year-survival rate of approximately 6%. Despite recent...
Our MoFlo Astrios serves or multidisciplinary Department of Biology through our open access Bioscience Technology Imaging and Cytometry Core Lab at the University of York. As a core instrumen...
DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
DATE: June 28, 2018TIME: 8:00AM PDTEnrichment of leukocytes from blood products like buffy coat, leukocyte reduction chambers (LRSC) or leukapheresis material can be time consuming...
DATE: June 27, 2018TIME: 08:00AM PDT CRISPR-Cas9 is a very versatile tool to discover more about your pathway or gene of interest. Its simplicity has led to an explosion in a...
Our Imaging and Cytometry Core Lab is in the Bioscience Technology Facility that serves a multidisciplinary Department of Biology as well as external users through our open access approach.&n...
Advances in DNA sequencing, based upon massively parallel sequencing, has resulted in dramatic advances in DNA sequence output in the past few years. It is now possible to generate terrabases...
The introduction of targeted therapies into the clinical management of lung adenocarcinoma has had a massive impact on patient care. Multiple driver mutations are now druggable and treatments...
Finding effective treatments for cancer is fundamentally a high-dimensional probabilistic planning, search, and optimization problem, characterized by thousands of molecular subty...
Crohn’s disease and ulcerative colitis also known as inflammatory bowel diseases or IBD, are characterized by chronic, recurrent inflammation of the gastrointestinal tract, which result...
Recent advancements in the precision medicine field have presented a great promise to provide innovative solutions to pharmaceutical and healthcare industry to help transform medicine. By fin...
Follow
